✦ LIBER ✦

Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report

✍ Scribed by Abdullah Altintas; Timucin Cil; Ilhan Kilinc; Muhammet Ali Kaplan; Orhan Ayyildiz

Publisher: Springer US
Year: 2007
Tongue: English
Weight: 165 KB
Volume: 84
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-007-9352-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P108 Central nervous system blastic phas

P108 Central nervous system blastic phase in chronic myeloid leukaemia during imatinib treatment

✍ A. Kiss; A. Ujfalusy; T. Csepany; Gy. Remenyi; P. Batar; E. Balogh; M. Udvardy 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 51 KB

6/155), high white cell number (13/155) (red cell unit) or low thrombocyte number (14/125) (thrombocyte unit). Summary: Donors with low hemoglobin levels have to be excluded from the blood donation service for 3 months. So, in theory haemoglobin concentration of all total blood units is suitable for

Imatinib mesylate-sensitive blast crisis

Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases

✍ Takehiro Higashi; Junichi Tsukada; Chiaki Kato; Atsushi Iwashige; Takamitsu Mizo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o